Previous Close | 1.1500 |
Open | 1.1700 |
Bid | 1.2400 x 2900 |
Ask | 1.2300 x 1400 |
Day's Range | 1.0000 - 1.3000 |
52 Week Range | 0.2430 - 2.9300 |
Volume | 6,485,386 |
Avg. Volume | 19,664,491 |
Market Cap | 57.797M |
Beta (5Y Monthly) | 0.13 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.6600 |
Earnings Date | Nov 18, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.75 |
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer, today issued the following letter from its chief executive officer, Alex Ovadia to its shareholders and the investment community:
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer, today announced financial results for the third quarter and nine months ended September 30, 2020 and corporate highlights.